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Introduction
Positron emission tomography (PET) has gained 
acceptance as a useful tool in the evaluation and 
management of head and neck squamous cell 
carcinoma (HNSCC).[1] It relies on radiolabeled 
18F-fluorodeoxyglucose (18F-FDG), a glucose analog 
that is transported into, but not metabolized by, 
actively dividing cells. Increased mitotic activity, and 
thus increased 18F-FDG uptake, underlies the ability of 
PET to detect tissues proliferating at an increased rate. 
18F-FDG uptake within a region of interest is reported 
as standardized uptake value (SUV), which accounts 
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Abstract
The goal of this study was to identify associations between positron emission tomography/computed tomography (PET/CT) 
maximum standardized uptake value (SUVmax) in patients presenting with head and neck squamous cell carcinoma (SCC) 
with tumor site, size, histologic differentiation, smoking, and diabetes. Charts of patients with oropharyngeal and laryngeal SCC 
who underwent 18F-fluorodeoxyglucose PET/CT scans were reviewed between May 2007 and August 2013. Statistical analyses 
included modeling log-transformed SUVmax values by tumor site, size, histologic differentiation, smoking status, and diabetes 
using unadjusted linear regressions. Differences were considered statistically significant for P < 0.05. A total of 111 patients 
(54 with oropharynx and 57 with larynx cancers) were included, 83 men and 28 women with an average age of 57.5 years old. 
There was a significantly higher pack-year smoking history (P = 0.005) in the larynx cancer group. While tumor T-stage was 
found to be significantly different (P < 0.0001), there was no difference in tumor size between the two groups: 3.16 cm and 
3.58 cm in the oropharynx and larynx, respectively (P = 0.55). In the oropharynx cohort, SUVmax was associated with both 
tumor size (P = 0.0001) and stage (P < 0.0002). Interestingly, SUVmax differed by tumor differentiation in the larynx (P = 0.04) 
but not the oropharynx (P = 0.71). Finally, there was no significant difference in SUVmax relative to diabetes and smoking status. 
PET/CT SUVmax correlated with both tumor size and stage in oropharyngeal cancer patients, and it correlated only with tumor 
differentiation but not the size or stage in the larynx. There were no significant differences in SUVmax by diabetes or smoking status.
Keywords: Larynx cancer, maximum standardized uptake value, oropharynx cancer, positron emission tomography/computed 
tomography, smoking, tumor differentiation






Address for correspondence: 
Dr. Rony K. Aouad, Department of Otolaryngology - Head and Neck 
Surgery, University of Kentucky, 800 Rose Street, C-240, 
Lexington, KY 40536, USA. 
E-mail: rony.aouad@uky.edu
How to cite this article: Pleitz JL, Sinha P, Dressler EV, Aouad RK. 
Correlation of positron emission tomography/computed tomography scan 
with smoking, tumor size, stage and differentiation in head and neck 
cancer patients. World J Nucl Med 2017;16:51-5.
This is an open access article distributed under the terms of  the Creative Commons 
Attribution‑NonCommercial‑ShareAlike 3.0 License, which allows others to remix, 
tweak, and build upon the work non‑commercially, as long as the author is credited 
and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
[Downloaded free from http://www.wjnm.org on Wednesday, April 11, 2018, IP: 128.163.8.74]
Pleitz, et al.: PET/CT mSUV with pathology and smoking
52 World Journal of Nuclear Medicine/Vol 16/Issue 1/January-March 2017
for injected activity level, incubation time, and patient 
height and weight. PET/computed tomography (CT) 
scans combine PET with low-dose CT images, thus 
providing both physiologic and anatomic information 
within the head and neck.
The use of 18F-FDG PET/CT for initial HNSCC 
staging, assessment of tumor response to therapy, and 
posttreatment surveillance has become increasingly 
common in clinical practice.[1] Yoon et al. demonstrated 
the superiority of 18F-FDG PET/CT over CT, magnetic 
resonance imaging, and ultrasonography in evaluating 
pretreatment locoregional tumor spread in HNSCC.[2] The 
usefulness of whole-body 18F-FDG PET/CT in detecting 
distant metastatic disease has also been shown.[3] In 
a recent meta-analysis of 2335 patients, Gupta et al. 
demonstrated the ability of 18F-FDG PET/CT to 
determine posttreatment tumor response, especially 
with studies performed more than 12 weeks following 
completion of therapy.[4] Paes et al. described the ability 
18F-FDG PET/CT to detect the perineural spread of 
HNSCC.[5] In his study of 63 consecutive HNSCC, 
Schwartz et al. found an association between baseline 
primary tumor FDG SUV and HNSCC outcomes.[6] 
Furthermore, Higgins et al. demonstrated a negative 
correlation between pretreatment primary tumor SUV 
and 2-year disease-free survival.[7]
The association of 18F-FDG PET/CT findings with 
specific HNSCC tumor characteristics is a recent topic of 
interest.[8] The primary goal of this study was to correlate 
PET/CT maximum SUV (SUVmax) of index lesions 
in patients presenting with HNSCC with tumor site, 
size, and histologic differentiation. The relationship of 
SUVmax with patient smoking status and diabetes was 
also investigated.
Materials and Methods
Collection of study data occurred following approval by 
the Institutional Review Board. The principle investigator 
retrospectively reviewed the charts of all patients initially 
diagnosed with HNSCC at our institution between 
May 2007 and August 2013. Exclusion criteria consisted 
of prior head and neck cancer treatment, incomplete 
patient records, and inadequate quality of the CT or 
PET/CT scans. Patients were divided based on tumor 
location, including oropharynx primary tumors and 
larynx primary tumors.
Gathered chart information included patient gender, age, 
pack-year smoking history, smoking status at the time of 
PET/CT, and the presence of diabetes. Tumor-specific 
variables, including location, T-stage, tumor size, 
differentiation, and locoregional spread were analyzed 
using pretreatment diagnostic CTs performed nearest the 
time of PET/CT. The tumor size was defined as the greatest 
tumor dimension (cm) measured in one of the three 
planes (axial, sagittal, or coronal). Histopathologic analyses 
were performed on specimens obtained using pretreatment 
biopsies and primary surgical excisions, when available. 
All pathologic specimens were formalin-fixed and stained 
using hematoxylin and eosin. Tumor differentiation was 
classified as well, moderate, or poor. The CT scans were 
excluded if they were low quality, thicker than 3 mm and 
the measurements were difficult to be made.
All patients scanned at our institution underwent 
pretreatment 18F-FDG PET/CT with a Biograph 
TruPoint 6 scanner (Siemens Healthcare, Germany) 
using lutetium oxyorthosilicate crystals. Scans were 
performed in two-dimensional mode. Before scanning, 
patients fasted at least 6 h (with the exception of water). 
Blood glucose levels were determined before injection 
of 18F-FDG. Scans were not performed on patients with 
glucose levels >200 mg/dL. Patients were weighed 
immediately before tracer injection. Following tracer 
injection, patients were given 10 mL gastrografin oral 
contrast per institutional guidelines. No intravenous 
contrast was used.
After voiding, patients underwent low-dose head and 
neck CT (256 × 256 matrix, 1.5 mm slice thickness). PET 
imaging of the head and neck (256 × 256 matrix, 1.5 mm 
slice thickness) was performed immediately thereafter. 
Two-bed positions were used, with an emission time 
of 5 min per position. Following this, “eyes-to-thigh” 
supine imaging was performed using low-dose, 
nonbreath holding CT (256 × 256 matrix, 3 mm slice 
thickness) followed by PET (256 × 256 matrix, 1.5 mm 
slice thickness). Seven bed positions were used, with an 
emission time of 3 min per position.
Somaris 5 software (Siemens Healthcare, Germany) with 
two iterative passes was used for image reconstruction. 
Images were interpreted by board-certified nuclear 
medicine physicians using a Syngo MMWP VE36A 
Workstation (Siemens Healthcare, Germany). Primary 
tumors were assessed with zoomed head and neck 
images. Images were reviewed in axial, coronal, and 
sagittal planes. SUVmax of lesions were calculated 
in three-dimensional by manually placing a region 
of interest in one plane to encompass the entire 
lesion [Figure 1]. Automated computer generated planes 
in the other two planes were then reviewed and adjusted 
if necessary to ensure that the entire tumor volume 
was included in all three planes and no physiologic 
structure with increased uptake (e.g., salivary glands) 
was included. SUV calculations were based on body 
volume (derived from patient weight), injected activity, 
and incubation time. Corrections for lean body mass 
were not made.
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All histopathologic and radiographic findings were 
reviewed at multidisciplinary tumor board and 
approved by our neuroradiologists and head and neck 
pathologists before their respective reports signed.
Statistical analysis correlating SUVmax with current 
smoking status, serum glucose level, T-stage, tumor size, 
and tumor differentiation was performed. The primary 
endpoint of SUVmax was log transformed to allow for 
parametric comparisons between cancer types using 
Fisher’s exact tests and 2-sample t-tests for categorical 
and continuous outcomes, respectively. Differences in 
log mean SUVmax between various demographic and 
clinical variables were considered in subsets of larynx 
or oropharynx cancer types. Strategies included linear 
regression models and Pearson correlations stratified 
by cancer type. Mean least square regression estimates 
with standard deviation (SD) of log SUVmax by 
categories are presented with corresponding P values. 
Differences were considered statistically significant 
for P < 0.05.
Results
A total of 111 patients were included in the study, and 
characteristics are presented in Table 1. 57 patients 
(41 males, 16 females) were included in the larynx 
cancer cohort whereas 54 patients (42 males, 12 females) 
were included in the oropharynx cohort. Mean age was 
57.46 years (SD 8.35) and 60.06 (SD 8.74) in the larynx 
and oropharynx groups, respectively (P = 0.11). Mean 
smoking history was 33.13 pack-years (SD 38.61) in 
the oropharynx cohort and 53.47 pack-years (SD 34.65) 
in the larynx cohort (P = 0.005). In the oropharynx 
group, 18 patients (34%) were current smokers 
whereas 20 patients (37.7%) had previously quit 
and 15 patients (28.3%) never smoked. In the larynx 
group, 37 patients (66.1%) were current smokers 
whereas 14 patients (25%) had previously quit and 
5 patients (8.9%) never smoked. Smoking status was 
unknown in one patient for both the oropharynx cancer 
and larynx cancer cohorts. There was a significant 
difference in smoking status between the two groups 
(P = 0.002).
Oropharynx T-staging was as follows: T1-tumors 
(n = 8, 14.8%), T2-tumors (n = 21, 38.9%), T3-tumors 
(n = 3, 5.6%), and T4-tumors (n = 22, 40.7%). Larynx 
T-staging was as follows: T1-tumors (n = 2, 3.5%), 
T2-tumors (n = 8, 14%), T3-tumors (n = 25, 43.9%), and 
T4-tumors (n = 22, 38.6%). Tumor T-staging between the 
two groups was significantly different (P < 0.0001). Mean 
oropharynx tumor size was 3.16 cm (SD 1.14) whereas 
mean larynx tumor size was 3.58 cm (SD 1.39). There 
was no significant difference in tumor size between the 
two groups (P = 0.09).
Overall log transformed mean SUVmax was 2.52 
(SD 0.40) in the oropharynx cohort and 2.50 (SD 0.40) in 
the larynx cancer cohort (P = 0.87). Scatter plots with the 
linear regression estimate plotted for the log transformed 
SUVmax by type are shown in Figures 2 and 3. In the 
oropharynx group, SUVmax is significantly associated 
with both tumor size (P < 0.0001) and stage (P = 0.0002). 
In the larynx group, there was no significant difference in 
SUVmax based on tumor size (P = 0.38) or stage (P = 0.25). 
Interestingly, SUVmax significantly is associated 
with larynx tumor differentiation (P = 0.04) but 
Figure 1: An example of maximum standardized uptake value of a 
left oropharynx tumor
Table 1: Patients characteristics




Men 42 77.78% 41 71.93%
Women 12 22.22% 16 28.07%
Age (years) 60.06 SD: 8.74 57.46 SD: 8.35 0.11
Smoking
Current 18 33.33% 37 64.91% 0.002
Previous 21 38.88% 14 24.56%
Never 15 27.77% 5 8.77%







I‑II 2 3.70% 5 8.77%
III‑IV 52 96.30% 52 91.23%
Size (cm) 3.16 SD: 1.14 3.58 SD: 1.39 0.09
Glucose 100.1 SD: 16.61 102.2 SD: 20.41 0.55
SUVmax (log 
transformed)
2.52 SD: 0.40 2.50 SD: 0.40 0.87
SD: Standard deviation; SUVmax: Maximum standardized uptake value
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not the oropharynx (P = 0.71). Furthermore, there 
was no significant difference between SUVmax, 
diabetes (P = 0.21 and P = 0.86) and smoking status 
(P = 0.99 and P = 0.56) in both groups, respectively. Model 
estimates for SUVmax are shown in Table 2.
Discussion
The use of 18F-FDG PET/CT for initial HNSCC 
staging, assessment of tumor response to therapy, and 
posttreatment surveillance has become increasingly 
common in clinical practice.[1] Numerous studies have 
shown the superiority of the PET/CT in determining 
pretreatment locoregional spread,[2] distant metastasis,[3] 
and posttreatment response in SCC of the head and neck 
of the head and neck.[4]
The primary goal of this study was to correlate PET/CT 
SUVmax with HNSCC tumor site, size, and histologic 
differentiation. Interestingly, this study showed that 
SUVmax correlated with tumor size (P < 0.0001) 
and stage (P < 0.0002) in the oropharynx only. It is 
important to note that the T-stage in the larynx does not 
Table 2: Associations with log transformed 





SD P SUVmax 
estimate
SD P
Tumor size (cm) 0.23 0.04 0.0001* 0.03 0.04 0.38
Stage
T1 2.08 0.13 0.0002* 2.58 0.28 0.25
T2 2.44 0.07 2.42 0.14
T3 3.03 0.19 2.41 0.08
T4 2.66 0.07 2.63 0.09
Differentiation
Poor 2.54 0.07 0.71 2.52 0.08 0.04*
Moderate 2.46 0.09 2.53 0.07
Well 2.67 0.4 1.94 0.22
Smoking
Current 2.52 0.1 0.99 2.5 0.07 0.56
Former 2.51 0.09 2.56 0.11
Never 2.51 0.11 2.33 0.18
Diabetes
Yes 2.66 0.13 0.21 2.47 0.17 0.86
No 2.48 0.06 2.51 0.06
*Unadjusted linear regression model estimates. SD: Standard deviation; 
SUVmax: Maximum standardized uptake value
Figure 3: Scatter plot with the linear regression estimate plotted for the log transformed maximum standardized uptake value by type for the 
whole-group
Figure 2: Scatter plot with the linear regression estimate plotted for 
the log transformed maximum standardized uptake value by type
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follow the size of the tumor but the subsites involved 
by the tumor and the mobility of the vocal cord: A 1 
cm tumor of the base of the tongue is staged a T1 of the 
oropharynx, but it could be staged a T3 of the larynx if 
the vocal cord is immobile. Similar results were found 
by Haerle et al.[8] in their study of newly diagnosed 
HNSCC patients where a positive association of 
SUVmax was found with T-classification. However, 
unlike Haerle’s study, we also observed a correlation 
between SUVmax and tumor histologic differentiation 
in the larynx: The higher the SUV, the higher tumor 
differentiation.
The secondary endpoint of this study was to examine 
the association between SUVmax and smoking history 
of the head and neck cancer patients. The relationship 
of SUVmax and tobacco usage is poorly reported in the 
literature. Na et al.[9] studied the association between 
smoking history, SUV, and nodal disease in nonsmall-cell 
lung cancer and he found the SUV of nonsmokers was 
less than the SUV of smokers (P < 0.001). Our results 
did not demonstrate a significant correlation between 
SUVmax and smoking status in either oropharynx or 
larynx cancer patients. To the best of our knowledge, 
this is the first study correlating SUVmax and smoking 
status in HNSCC.
Despite those interesting findings, our study has some 
limitations. The study is retrospective by design. In 
addition, pack-year, which is considered to be the 
standard way of measuring the smoking history, 
was determined based on patient responses recorded 
during their initial presentation to the clinic. This 
measure may have been flawed given its subjectivity 
and reliance on “rounded” numbers. Future studies 
may potentially overcome this by analyzing objective 
measures of tobacco use (e.g., serum cotinine levels). 
In addition, it is challenging to compare oropharynx 
and larynx cancers SUVmax with regards to T-size 
given the differences in TNM staging between the two 
subsites. A large tumor in the oropharynx may only 
be considered a T1–T2 (<4 cm without deep muscle 
invasion) while a small tumor of the larynx with 
immobility of the vocal fold is a T3. Furthermore, this 
study did include several tumors <1.5 cm, in which 
accuracy of SUVmax decreases.[1] The effect of these 
inaccuracies was likely small, as these tumors only 
accounted for five patients in the oropharynx cohort 
and three patients in the larynx cohort. Finally, the 
method we used to measure the size of the tumor may 
be another source of weakness despite all our efforts 
to minimize this human error.
Conclusion
Our study showed that SUVmax correlated with both 
tumor size and stage in oropharyngeal cancers, but not 
histologic differentiation unlike in the larynx where 
SUVmax correlated with tumor differentiation but not with 
size and stage of the tumor. We did not find any correlation 
between SUVmax and diabetes or smoking status. These 
findings are sure interesting, however future research 
is needed to help determine the clinical significance of 
PET/CT’s SUVmax in head and neck cancer, especially 
in counseling patients before their treatment.
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